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Stable obstructive coronary artery disease (CAD) and acute
coronary syndromes (ACS) result from the complex inter-
play between genetic factors and environmental exposures
over time. However, few studies have provided clarity
around the interactions between different genes and envi-
ronmental exposures and the resultant effects on cardiovas-
cular (CV) phenotype. Even the model of gene–environment
interaction is likely oversimplistic as there are likely to be
multiple genes involved in: 1) the initiation of atheroscle-
rosis; and 2) modiﬁcation of the subclinical course, inter-
playing with different environmental factors to inﬂuence the
timing and the type of clinical presentation (Fig. 1). In this
issue of the Journal, Tsimikas et al. (1) link for the ﬁrst time
the potential interactions between genetic factors inﬂuencing
inﬂammation and exposure to modiﬁed lipids, and how
this may inﬂuence the development of CAD and CV events.See page 1724Cholesterol carried within apolipoprotein B-100 (apoB)-
containing lipoproteins is continuously associated with the
risk for fatal and nonfatal myocardial infarction (MI) (2).
Furthermore, oxidized phospholipids (OxPLs), and in
particular OxPLs associated with apoB (OxPL/apoB), pre-
dict the risk for cardiovascular events and reclassify about
30% of patients considered at intermediate risk (3). In
part, higher OxPL may reﬂect higher absolute levels of
apoB-containing lipoproteins and higher non–high-density
lipoprotein cholesterol levels, but also could be enhanced
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Steven Nissen, MD, served as Guest Editor for this paper.could be driven via principally genetic factors or via envi-
ronmental factors associated with higher oxidative states,
such as diabetes or chronic kidney disease. A substantive
body of classic epidemiology and Mendelian randomization
studies now implicates lipoprotein (LP) (a) as a causal factor
in cardiovascular disease, although the relationship with risk
does not appear to be continuous but rather curvilinear, with
greatest risk observed in the highest quintile (4). Previously,
Taleb et al. (5) demonstrated that OxPLs are preferentially
carried by Lp(a) compared with other apoB-containing
lipoproteins. Thus, in part, the risk related to higher Lp(a)
levels could result from its relationship with OxPLs.
OxPLs are pro-inﬂammatory and destabilize atheroscle-
rotic plaques, further amplifying any intrinsic inﬂammatory
potential within patients. It is plausible, therefore, that
the interplay between OxPLs and inﬂammation results in
the severest cardiovascular phenotypes, whether that is the
presence of angiographic CAD or acute CV events. Tsi-
mikas et al. (1) studied 499 consecutive patients undergoing
clinically indicated coronary angiography who were geno-
typed for common variants in the IL-1 locus that inﬂuence
the pro-inﬂammatory cytokine IL-1b; speciﬁcally, IL1A
(þ4,845), IL1B (þ3,954 and 511) and 4 speciﬁc haplo-
types (IL-1[þ]) known to be associated with higher levels of
the inﬂammatory cytokine IL-1b were compared with
haplotypes associated with lower levels of IL-1b (IL-1[]).
The pro-inﬂammatory haplotypes studied have also been
previously associated with high circulating levels of C-
reactive protein (CRP), presumably via IL-1b–mediated
stimulation of IL-6, which is the main driver for CRP
production. Using a deﬁnition of CAD as diameter stenosis
>50%, Tsimikas et al. (1) assessed the relationship between
IL-1(þ) status and the presence or absence of CAD across
quartiles of OxPL/apoB and Lp(a) using cross-sectional
data and essentially a case–control design. Interestingly,
IL-1(þ) and IL-1() subjects were well-matched and did
not differ in the presence or absence of CAD or in the extent
of CAD, OxPL/apoB, or Lp(a).
In their analyses (for simplicity described here as) focusing
on quartile 4 (Q4) versus quartile 1 (Q1) of lipid parameter,
OxPL/apoB was associated with an increased risk for CAD
(odds ratio [OR]: 1.96) overall, which among IL-1(þ) pa-
tients was even stronger (OR: 2.84) but was absent among
the IL-1() cohort. If genetic inﬂuences play a signiﬁcant
role in modulating phenotype, we would expect the impact
of these to occur in younger patients. This is exactly what the
authors observed, with a rather impressive signiﬁcant OR
of 7.03 among the <60-year age strata when assessing the
risk of IL-1(þ) genotype among those with OxPL/apoB Q4
versus Q1. By contrast, there was no signiﬁcant association
with CAD among those age <60 years who were IL-1();
and among those >60 years of age, there was no signiﬁcant
association between OxPL/apoB and risk irrespective of
genotype, suggesting that the risk from elevated levels of
OxPL/apoB is greatest among those who are younger
and who have an IL-1(þ) inﬂammatory haplotype (p for
Figure 1
Schematic of the Interaction Between Multiple Genes and Multiple Exposures to Inﬂuence Coronary Artery Disease and
Acute Coronary Syndromes
IL ¼ interleukin.
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1736interaction ¼ 0.007). Similarly, when the risk associated
with higher Lp(a) was assessed (Q4 vs. Q1), the results were
qualitatively similar (OR: 9.0 in the <60-year age stratum
for IL-1[þ] status), with evidence of increased risk partic-
ularly among younger subjects with a pro-inﬂammatory
IL-1(þ) haplotype (p for interaction ¼ 0.019). Further
data to support this potentially biologically relevant inter-
action were also provided by the authors in the form of data
that showed that patients with IL-1(þ) haplotype and
OxPL/apoB levels greater than median presented for clini-
cally warranted cardiac catheterization 3.9 years earlier, with
the corresponding ﬁgure for Lp(a) being 3.5 years. This
interaction was not only relevant for the presence of
angiographic disease, but as the authors show with longi-
tudinal data, the same consistent interactions were observed
with risk for future acute CV events. For instance, when
IL-1(þ) and IL-1() genotype were compared crudely, no
real trend emerged with longitudinal risk. However, when
data were stratiﬁed by haplotype and OxPL/apoB exposure,
then 4-year risk for death, MI, stroke, and/or need for
revascularization were greatest among those with IL-1(þ)
haplotypes with OxPL/apoB greater than median (p ¼
0.002 vs. all other groups), with evidence of an interaction
(p for interaction ¼ 0.002). Qualitatively similar results were
observed for Lp(a), with the greatest risk observed among
IL-1(þ) genotype when Lp(a) was greater than median
compared with all other combinations (p ¼ 0.034; p for
interaction ¼ 0.014). Tsimikas et al. (1) is the ﬁrst study to
provide compelling evidence that inﬂammation modulates
oxidized lipids to inﬂuence the presentation of CAD.So how might the IL-1 locus inﬂuence CAD? Firstly,
inﬂammation is known to be integral to the pathophysi-
ology of coronary atherosclerosis and ACS, and histo-
pathologic data indicate that the pro-inﬂammatory cytokine
IL-1 is abundant in atherosclerotic tissue compared with
healthy controls and that levels are particularly increased
within the vessel wall in subjects with ACS. The naturally
occurring antagonist of IL-1, IL-1 receptor antagonist
(IL-1Ra), is also found in atherosclerotic tissue (speciﬁcally
the endothelium), and the balance between these 2 cyto-
kines may determine a number of cellular responses. In-
deed, in diseases known to have an inﬂammatory etiology,
such as inﬂammatory bowel disease, a relative excess
of IL-1 to IL-1Ra has been associated with chronicity
and severity of symptoms. The IL-1 locus on chromosome
2 (2q13) contains 3 important genes (IL1A, IL1B, and
IL1RN) coding for 2 pro-inﬂammatory cytokines, IL-1a
and IL-1b, and their antagonist, IL-1Ra, in partial linkage
disequilibrium. These genes appear to be functional with
genetic variants associated with differences in levels of
CRP as well as IL-1a, IL-1b, and IL-1Ra in both plasma
and within the endothelium (6). Furthermore, genetic
variations at the IL-1 locus, speciﬁcally, IL1A (889 or
þ4,845), IL1B (511 or þ3,953), and IL-1RN (þ2,018),
have been associated with a number of diseases that have
an inﬂammatory etiology, including CAD (7,8), and this
risk is further increased in the presence of environmental
factors such as Chlamydia pneumonia (9). Among pati-
ents with diabetes, genetic variations in IL1RN(þ2,018)
(known to be associated with lower circulating levels of
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1737IL-1Ra) are also associated with an increased risk for
CAD (10). In other studies, although the IL-1 haplotype
did not appear to inﬂuence the development of stable
CAD versus ACS, it did appear to inﬂuence the endo-
thelial response during ACS. In particular, the presence of
gene variants in IL1RN (þ2,018) and IL1B (511), which
are in linkage disequilibrium, resulted in an augmented
pro-inﬂammatory endothelial response during ACS, asso-
ciated with a greater change in von Willebrand factor,
E-selectin, thromobomodulin, and troponin within the ﬁrst
48 h of a non–ST-segment elevation ACS and predicted
the response to low-molecular-weight heparin (11,12).
Furthermore, the vessel wall in atherosclerosis is rich both
in IL-1b (13) and in IL-1Ra and (14). Atherectomy speci-
mens have shown that IL-1b messenger ribonucleic acid
is up-regulated in patients with ACS compared with
stable CAD (15). Thus, there is good evidence that the
IL-1 locus is implicated in atherosclerosis and its many
presentations.
Is there evidence that the interplay between the IL-1
system and lipids inﬂuences the vascular phenotype within
patients? First, IL-1a and IL-1b are known to be produced
by a number of cell types, including endothelial cells and
inﬂammatory cells such as mononuclear cells in response to
inﬂammatory stimuli. Although IL-1a remains mostly in
the cytosol (where it functions as an autocrine messenger),
IL-1b is cleaved for biological activity by a protease called
caspase-1 and secreted. Minimally modiﬁed low-density
lipoprotein (LDL) induces gene expression of IL-1b
in human peripheral blood mononuclear cells in a dose-
dependent manner (16). The interaction between IL-1
and OxLDL may be important in ACS, because mono-
cytes from ACS patients show increased production of IL-
1b in response to OxLDL compared with patients with
stable CAD or normal controls (17). The interaction be-
tween environmental factors and IL-1 may be modiﬁed by
genetic variation; for example, monocytes from patients
deﬁcient in the CD36 antigen secrete less IL-1b upon
stimulation by OxLDL (18). Pre-incubation of human
umbilical vein endothelial cells with IL-1 results in the
increased expression of receptors for LDL (LOX-1) and
increased uptake and degradation of LDL from serum
compared with unstimulated cells (19). Pre-incubation of
human umbilical vein endothelial cells with OxLDL in turn
augments IL-1a–mediated expression of adhesion molecules
(VCAM-1) in endothelial cells (20). These in vitro or
ex vivo studies provide a robust biological framework for the
clinical ﬁndings of Tsimikas et al. (1). If these ﬁndings are
replicated or validated in prospective studies on a large scale,
they could represent a new paradigm in our understanding of
how inﬂammation modiﬁes environmental exposure to
lipids.
Finally, the ﬁndings are directly relevant to the ongoing
CANTOS (Canakinumab Anti-inﬂammatory Thrombosis
Outcomes Study) (21), which has randomized patients
with stable cardiovascular disease and a high CRP to amonoclonal antibody to IL-1b (canakinumab). Based on the
present study, one would expect the agent to be particularly
effective among those with a speciﬁc pro-inﬂammatory IL-1
haplotype and higher levels of OxPL/apoB or Lp(a). In vitro
studies have already shown that statins can reduce IL-1
production in endothelial cells, in response to a number
of pro-inﬂammatory stimuli (22), hence, treatments that
directly target IL-1 may reduce cardiovascular risk on top
of usual care. We await with interest the results of the
CANTOS trial and to see whether the IL-1 system has
ﬁnally come of age in cardiovascular disease.
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